Literature DB >> 32250385

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.

Giacomo Grasselli1,2, Alberto Zangrillo3,4, Alberto Zanella1,2, Massimo Antonelli5,6, Luca Cabrini7, Antonio Castelli8, Danilo Cereda9, Antonio Coluccello10, Giuseppe Foti11,12, Roberto Fumagalli11, Giorgio Iotti13, Nicola Latronico14,15, Luca Lorini16, Stefano Merler17, Giuseppe Natalini18, Alessandra Piatti7, Marco Vito Ranieri19, Anna Mara Scandroglio3, Enrico Storti20, Maurizio Cecconi21,22, Antonio Pesenti1,2.   

Abstract

Importance: In December 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) emerged in China and has spread globally, creating a pandemic. Information about the clinical characteristics of infected patients who require intensive care is limited. Objective: To characterize patients with coronavirus disease 2019 (COVID-19) requiring treatment in an intensive care unit (ICU) in the Lombardy region of Italy. Design, Setting, and Participants: Retrospective case series of 1591 consecutive patients with laboratory-confirmed COVID-19 referred for ICU admission to the coordinator center (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy) of the COVID-19 Lombardy ICU Network and treated at one of the ICUs of the 72 hospitals in this network between February 20 and March 18, 2020. Date of final follow-up was March 25, 2020. Exposures: SARS-CoV-2 infection confirmed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs. Main Outcomes and Measures: Demographic and clinical data were collected, including data on clinical management, respiratory failure, and patient mortality. Data were recorded by the coordinator center on an electronic worksheet during telephone calls by the staff of the COVID-19 Lombardy ICU Network.
Results: Of the 1591 patients included in the study, the median (IQR) age was 63 (56-70) years and 1304 (82%) were male. Of the 1043 patients with available data, 709 (68%) had at least 1 comorbidity and 509 (49%) had hypertension. Among 1300 patients with available respiratory support data, 1287 (99% [95% CI, 98%-99%]) needed respiratory support, including 1150 (88% [95% CI, 87%-90%]) who received mechanical ventilation and 137 (11% [95% CI, 9%-12%]) who received noninvasive ventilation. The median positive end-expiratory pressure (PEEP) was 14 (IQR, 12-16) cm H2O, and Fio2 was greater than 50% in 89% of patients. The median Pao2/Fio2 was 160 (IQR, 114-220). The median PEEP level was not different between younger patients (n = 503 aged ≤63 years) and older patients (n = 514 aged ≥64 years) (14 [IQR, 12-15] vs 14 [IQR, 12-16] cm H2O, respectively; median difference, 0 [95% CI, 0-0]; P = .94). Median Fio2 was lower in younger patients: 60% (IQR, 50%-80%) vs 70% (IQR, 50%-80%) (median difference, -10% [95% CI, -14% to 6%]; P = .006), and median Pao2/Fio2 was higher in younger patients: 163.5 (IQR, 120-230) vs 156 (IQR, 110-205) (median difference, 7 [95% CI, -8 to 22]; P = .02). Patients with hypertension (n = 509) were older than those without hypertension (n = 526) (median [IQR] age, 66 years [60-72] vs 62 years [54-68]; P < .001) and had lower Pao2/Fio2 (median [IQR], 146 [105-214] vs 173 [120-222]; median difference, -27 [95% CI, -42 to -12]; P = .005). Among the 1581 patients with ICU disposition data available as of March 25, 2020, 920 patients (58% [95% CI, 56%-61%]) were still in the ICU, 256 (16% [95% CI, 14%-18%]) were discharged from the ICU, and 405 (26% [95% CI, 23%-28%]) had died in the ICU. Older patients (n = 786; age ≥64 years) had higher mortality than younger patients (n = 795; age ≤63 years) (36% vs 15%; difference, 21% [95% CI, 17%-26%]; P < .001). Conclusions and Relevance: In this case series of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Lombardy, Italy, the majority were older men, a large proportion required mechanical ventilation and high levels of PEEP, and ICU mortality was 26%.

Entities:  

Mesh:

Year:  2020        PMID: 32250385      PMCID: PMC7136855          DOI: 10.1001/jama.2020.5394

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

1.  The variability of critical care bed numbers in Europe.

Authors:  A Rhodes; P Ferdinande; H Flaatten; B Guidet; P G Metnitz; R P Moreno
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

2.  Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.

Authors:  Matt Arentz; Eric Yim; Lindy Klaff; Sharukh Lokhandwala; Francis X Riedo; Maria Chong; Melissa Lee
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

3.  Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response.

Authors:  Giacomo Grasselli; Antonio Pesenti; Maurizio Cecconi
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

4.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.

Authors:  Xiaobo Yang; Yuan Yu; Jiqian Xu; Huaqing Shu; Jia'an Xia; Hong Liu; Yongran Wu; Lu Zhang; Zhui Yu; Minghao Fang; Ting Yu; Yaxin Wang; Shangwen Pan; Xiaojing Zou; Shiying Yuan; You Shang
Journal:  Lancet Respir Med       Date:  2020-02-24       Impact factor: 30.700

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  8 in total
  1910 in total

1.  Look at the wood and not at the tree: The Microbiome in Chronic Obstructive Lung Disease and Cystic Fibrosis.

Authors:  Eduard Monsó
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2019-06-01       Impact factor: 4.872

2.  Outcomes of renal replacement therapy in the critically ill with COVID-19.

Authors:  E Burke; E Haber; C W Pike; R Sonti
Journal:  Med Intensiva (Engl Ed)       Date:  2021-02-18

3.  Factors influencing liberation from mechanical ventilation in coronavirus disease 2019: multicenter observational study in fifteen Italian ICUs.

Authors:  Lorenzo Gamberini; Tommaso Tonetti; Savino Spadaro; Gianluca Zani; Carlo Alberto Mazzoli; Chiara Capozzi; Emanuela Giampalma; Maria Letizia Bacchi Reggiani; Elisabetta Bertellini; Andrea Castelli; Irene Cavalli; Davide Colombo; Federico Crimaldi; Federica Damiani; Alberto Fogagnolo; Maurizio Fusari; Emiliano Gamberini; Giovanni Gordini; Cristiana Laici; Maria Concetta Lanza; Mirco Leo; Andrea Marudi; Giuseppe Nardi; Irene Ottaviani; Raffaella Papa; Antonella Potalivo; Emanuele Russo; Stefania Taddei; Carlo Alberto Volta; V Marco Ranieri
Journal:  J Intensive Care       Date:  2020-10-15

Review 4.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Authors:  Andrew M South; Tammy M Brady; Joseph T Flynn
Journal:  Hypertension       Date:  2020-05-05       Impact factor: 10.190

5.  AKI in Hospitalized Patients with and without COVID-19: A Comparison Study.

Authors:  Molly Fisher; Joel Neugarten; Eran Bellin; Milagros Yunes; Lindsay Stahl; Tanya S Johns; Matthew K Abramowitz; Rebecca Levy; Neelja Kumar; Michele H Mokrzycki; Maria Coco; Mary Dominguez; Kalyan Prudhvi; Ladan Golestaneh
Journal:  J Am Soc Nephrol       Date:  2020-07-15       Impact factor: 10.121

6.  Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology.

Authors:  Maicon Falavigna; Verônica Colpani; Cinara Stein; Luciano Cesar Pontes Azevedo; Angela Maria Bagattini; Gabriela Vilela de Brito; José Miguel Chatkin; Sergio Cimerman; Mirian de Freitas Dal Ben Corradi; Clovis Arns da Cunha; Flávia Cordeiro de Medeiros; Haliton Alves de Oliveira Junior; Leandro Genehr Fritscher; Marcelo Basso Gazzana; Débora Dalmas Gräf; Lays Pires Marra; Jessica Yumi Matuoka; Michelle Silva Nunes; Daniela Vianna Pachito; Cássia Garcia Moraes Pagano; Patrícia do Carmo Silva Parreira; Rachel Riera; Amilton Silva; Bruno de Melo Tavares; Alexandre Prehn Zavascki; Regis Goulart Rosa; Felipe Dal-Pizzol
Journal:  Rev Bras Ter Intensiva       Date:  2020-07-13

7.  Stem Cell-Based Therapy for Coronavirus Disease 2019.

Authors:  Robert Chunhua Zhao
Journal:  Stem Cells Dev       Date:  2020-04-17       Impact factor: 3.272

8.  The Natural History of a Patient With COVID-19 Pneumonia and Silent Hypoxemia.

Authors:  Nicholas Hornstein; Gilad M Jaffe; Kelley Chuang; Jaime Betancourt; Guy W Soo Hoo
Journal:  Fed Pract       Date:  2021-04

Review 9.  Impact of COVID-19 pandemic on chronic diseases care follow-up and current perspectives in low resource settings: a narrative review.

Authors:  Ginenus Fekadu; Firomsa Bekele; Tadesse Tolossa; Getahun Fetensa; Ebisa Turi; Motuma Getachew; Eba Abdisa; Lemessa Assefa; Melkamu Afeta; Waktole Demisew; Dinka Dugassa; Dereje Chala Diriba; Busha Gamachu Labata
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-06-15

10.  Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series.

Authors:  Anish R Mitra; Nicholas A Fergusson; Elisa Lloyd-Smith; Andrew Wormsbecker; Denise Foster; Andrei Karpov; Sarah Crowe; Greg Haljan; Dean R Chittock; Hussein D Kanji; Mypinder S Sekhon; Donald E G Griesdale
Journal:  CMAJ       Date:  2020-05-27       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.